Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lenalidomide (Primary) ; Tafasitamab (Primary) ; Tazemetostat (Primary) ; Zanubrutinib (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Therapeutic Use
Acronyms SWOG 2207

08 Dec 2024 Trial design presented at 66th American Society of Hematology Annual Meeting and Exposition.
08 Dec 2024 Planned number of patients changed from 227 to 180.
21 Jul 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com